A recent study found that while treatment outcomes for a CLL therapy are comparable in clinical trials and the real-world setting, adverse events are increased in the latter. READ MORE
A long-term post-hoc analysis compared the effects of three therapy regimens for the initial treatment of patients with a type of advanced-stage B-cell malignancy.
Twenty-four-month event-free survival may be a surrogate for overall survival in patients with peripheral T-cell lymphoma, according to a recent study.
Researchers analyzed the impact of a novel therapy on health-related quality of life in patients with a chronic-phase leukemia subtype.
Breast implant-associated anaplastic large-cell lymphoma is rare, but diagnoses seem to be increasing as both patients and clinicians become more aware of this complication.
Research in Review
Consolidation with arsenic trioxide allows for decreased anthracycline dosing while maintaining survival rates and a low risk of relapse in pediatric patients with acute promyelocytic leukemia.
A recent study showed improved long-term survival outcomes and QoL for patients with MCL receiving TKI therapy compared with those receiving standard of care.
A weekly recap of trending news and research, including a special report on clinical pathways for advance stage gastric cancer and novel therapies for chronic lymphocytic leukemia.
Patients with chronic myeloid leukemia who attempt to discontinue tyrosine kinase inhibitor therapy for a second time after a first unsuccessful attempt have strong treatment-free remission rates.